
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
NeoGenomics is a diagnostics & research business based in the US. NeoGenomics shares (NEO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.48 – a decrease of 4.33% over the previous week. NeoGenomics employs 2,100 staff and has a trailing 12-month revenue of around $644.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $13.48 |
---|---|
52-week range | $12.13 - $19.12 |
50-day moving average | $16.25 |
200-day moving average | $15.16 |
Wall St. target price | $20.45 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-0.61 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.51 from 2025-02-10
1 week (2025-02-05) | -4.12% |
---|---|
1 month (2025-01-13) | 6.97% |
3 months (2024-11-13) | -17.77% |
6 months (2024-08-13) | -18.02% |
1 year (2024-02-12) | -10.88% |
---|---|
2 years (2023-02-10) | 8.86% |
3 years (2022-02-11) | 22.57 |
5 years (2020-02-12) | 34.525 |
Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Revenue TTM | $644.1 million |
---|---|
Gross profit TTM | $280.4 million |
Return on assets TTM | -2.76% |
Return on equity TTM | -8.38% |
Profit margin | -12.07% |
Book value | $7.09 |
Market Capitalization | $1.7 billion |
TTM: trailing 12 months
We're not expecting NeoGenomics to pay a dividend over the next 12 months.
NeoGenomics's shares were split on a 1:100 basis on 15 April 2003 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.
Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $12.125 up to $19.115. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 1.183. This would suggest that NeoGenomics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc.